GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rain Enhancement Technologies Holdco RAIN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.54

+7.79%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Rain Enhancement Technologies Holdco

From its filings with the US Securities and Exchange Commission

SEC filings

Rain Enhancement Technologies Holdco is based in Naples, Florida and is incorporated in Massachusetts. Its shares trade on Nasdaq under the ticker RAIN. The SEC classifies its business as misc industrial & commercial machinery & equipment. In the fiscal year to 31 December 2025, it reported a net loss of $9.1m. At that date it held total assets of $1.8m and shareholders' equity of −$12.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
23 Apr 2021
Employees
63
Head office
4851 TAMIAMI TRAIL N, NAPLES, FL, 34103
Incorporated in
MA
Classification
Misc Industrial & Commercial Machinery & Equipment
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Avanish VellankiChairman of the Board, Chief Executive Officer, Co-Founder, since 2017$2.2m
  • Dr. Robert DoebelePresident, Co-Founder, Chief Scientific Officer Chief Medical Officer$1.4m
  • Ms. Joy BrucePrincipal Financial Officer, Principal Accounting Officer
  • Mr. Franklin BergerLead Independent Director$117,752
  • Mr. Aaron DavisIndependent Director$82,752
  • Dr. Gorjan HrustanovicIndependent Director$80,252
  • Mr. Tran NguyenIndependent Director$94,252
  • Mr. Peter RadovichIndependent Director$89,252
  • Ms. Stefani WolffIndependent Director$83,252

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
28
Environment
29
Social
38
Governance
16
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Rain Oncology focuses on precision oncology therapies targeting oncogenic drivers for cancer patients.
  • Milademetan is an oral small molecule inhibitor of the p53-MDM2 complex reactivating p53 in MDM2-dependent cancers.
  • The company employs 63 full-time employees with a clinical-stage development focus in Pharmaceuticals.

Weaknesses

  • Rain Oncology is a clinical-stage company with no approved products yet in the US market.
  • The company's sole product candidate milademetan faces regulatory hurdles in clinical trials.
  • Rain Oncology has limited financial resources as a newly listed IPO company.

Opportunities

  • The growing market for precision oncology therapies in the US healthcare sector presents expansion potential.
  • The MDM2-dependent cancer segment offers a targeted therapeutic niche for milademetan.
  • The US pharmaceutical industry continues to invest in innovative cancer treatments.

Threats

  • Regulatory delays in FDA approval processes for milademetan could impact development timelines.
  • Competition from established oncology therapies in the US market poses a risk.
  • Economic downturns may reduce funding for clinical-stage pharmaceutical companies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.